SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists

enGene Therapeutics Inc. (NASDAQ:ENGN)

CA · Delayed Price · Currency is USD
1.70-0.04 (-2.57%)
 
Market Cap113.89M-77.2%
Revenue (ttm)0
Net Income-4.90M
EPS-0.28
Shares Out66.99M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend DateFeb 2, 2015
Volume481,975.168
Open1.75
Previous Close1.75
Day's Range1.68 - 1.75
52-Week Range1.40 - 12.25
Betan/a
AnalystsHold
Price Target3.00(+76.46%)
Earnings DateDec 28, 2026
-3.15% (1D)
No price history available.
Insider Score
/ 100
ENGN Insider Score

enGene Therapeutics Inc. has a live Insider Score.

Scored on 1 qualifying trade from 1 insider in the last 90 days.

Unlock the score

About ENGN

Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.

Address
4868 Rue Levy, Montreal, QC, H4R 2P1, CA
Market Cap
114 million
Employees
82
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$10.05K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
-3.15%
5 Days
-14.65%
1 Month
-8.65%
6 Months
-76.75%
1 Year
-77.19%

$ENGN stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ENGN holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ENGN's directors and management

Net Shares Purchased by Insiders−6k−3k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ENGN Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ENGN patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ENGN from public contracts

Source: USAspending.gov

ENGN Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

Members only

The live Insider Score for ENGN is included with Insider Access.

Unlock Insider Score

Bull Case vs Bear Case

AI-generated from ENGN’s recent data — informational, not investment advice

Generating analysis…

Insider Score

Our 0–100 Insider Score and the signals behind it.

Members only

The live Insider Score and its full factor breakdown are included with Insider Access.

Unlock Insider Score

Recent Insider Activity

Buys
1
Sells
0
Buy Value
$10.05K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.